What it is
Pemvidutide acts on two receptors, GLP-1 and glucagon, with equal strength at each12. GLP-1 is a hormone your gut releases when you eat14, and glucagon is a hormone that raises blood sugar. Drugs that act on the GLP-1 receptor lower weight through effects on appetite3. Drugs that act on the glucagon receptor work directly on the liver, making it burn more fat and make less of it3. Pemvidutide carries a fat-and-sugar chain (a glycolipid, called EuPort) that binds to albumin, a protein in the blood, and slows how fast it's cleared2. It was designed this way to last long enough for once-a-week injections under the skin24.
What makes it distinct
In its phase 2b liver trial, people got their full trial dose from the first injection, with no step-up period (dose titration)4.
What the evidence shows
Its results in people so far come from phase 1 and phase 2 trials1410. In a 12-week trial, 94 adults with obesity or overweight and fatty liver disease (MASLD) took pemvidutide or a placebo, and liver fat fell more on pemvidutide3. In the 64 of them who continued to 24 weeks, the result held5. IMPACT, a phase 2b trial, enrolled 212 adults with MASH, the progressive form of fatty liver disease, and liver scarring (fibrosis) at stage 2 or 3, short of cirrhosis, confirmed by biopsy (a small sample of liver tissue)4312. At 24 weeks, MASH resolved on biopsy, without scarring getting worse, in more people on pemvidutide than on placebo4. It did not meet its other main goal, an improvement in scarring on biopsy, at that point4. For weight, MOMENTUM, a 48-week phase 2 trial in 391 adults with obesity or overweight and no diabetes, has finished76. Altimmune, which is developing it, reported in 2023 that people on pemvidutide lost more weight than people on placebo61. For alcohol use disorder, Altimmune reported in July 2026 that in a phase 2 trial in 100 people, pemvidutide reduced heavy drinking days more than placebo over 24 weeks1. In MOMENTUM, nausea and vomiting were the most common side effects, mostly mild to moderate6.
Open questions
- Whether it improves liver scarring. In IMPACT, biopsies at 24 weeks didn't show more improvement in scarring than placebo4. At 48 weeks, Altimmune reported that two tests linked to scarring that don't need a biopsy, a blood test and a scan of liver stiffness, improved more than on placebo11. Its phase 3 trial, PERFORMA, started in 2026 and checks biopsies at 52 weeks; Altimmune expects those results in 202918.
- Full MOMENTUM results. No results are posted on its trial record7.
- Its effect on drinking in a larger trial. RECLAIM was a phase 2 trial in 100 people1.
- Whether it will be developed for weight on its own. Altimmune's 2026 description lists it for MASH, alcohol use disorder and alcohol-associated liver disease; obesity isn't on that list1.
Worth knowing
For MASH, the FDA has given it Breakthrough Therapy designation1. The FDA describes this as a process meant to speed up the development and review of drugs for serious conditions13. It isn't an approval1. The code name ALT-801, which pemvidutide once had, was also used for an unrelated cancer drug built from an immune-system protein (interleukin-2), so a search for that code can turn up studies of a different molecule29.
Sources
- Altimmune, Second Quarter 2026 Financial Results and Business Update, 12 August 2026 (SEC Form 8-K, Exhibit 99.1)
- Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of NASH. Sci Rep 2022 (full text)
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J Hepatol 2025
- Safety and efficacy of weekly pemvidutide versus placebo for MASH (IMPACT): 24-week results from a phase 2b study. Lancet 2025
- Safety and efficacy of 24 weeks of pemvidutide in MASLD: a randomized, controlled clinical trial. JHEP Rep 2025
- Altimmune press release, 30 November 2023: Positive topline results from MOMENTUM 48-week phase 2 obesity trial of pemvidutide (SEC Form 8-K, Exhibit 99.1)
- ClinicalTrials.gov NCT05295875: ALT-801 in the treatment of obesity (MOMENTUM)
- ClinicalTrials.gov NCT07795164: Phase 3 study of pemvidutide in noncirrhotic MASH (PERFORMA)
- Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53, in patients with advanced malignancies. Clin Cancer Res 2011
- ClinicalTrials.gov NCT05006885: ALT-801 in overweight and obese subjects with NAFLD
- Altimmune press release, 19 December 2025: 48-week topline data from the IMPACT phase 2b trial of pemvidutide in MASH (SEC Form 8-K, Exhibit 99.1)
- ClinicalTrials.gov NCT05989711: IMPACT, pemvidutide in non-cirrhotic NASH
- FDA: Breakthrough Therapy
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)
More in GLP-1 and glucagon drugs